Copyright © 2000 by the European Society of Cardiology.
Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Results from the DIGAMI study
a Department of Cardiology, Karolinska Hospital, Stockholm, Sweden
b Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
c SBL Vaccine AB, Stockholm, Sweden
revised July 12, 1999; accepted July 22, 1999
Abstract
Aims The aim of the present analysis was to estimate the cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus based on the results of the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. In this study 620 patients with diabetes mellitus and acute myocardial infarction were randomized to intense insulin treatment (insulin group) or to serve as controls given standard antidiabetic therapy. Mortality was significantly reduced in the insulin group.
Methods and Results The cost-effectiveness ratio was estimated as the incremental cost per life-year and quality-adjusted life-year gained of intense insulin treatment. The incremental costs were estimated as the difference in health care costs and indirect costs (labour production) during the first year of follow-up plus the future costs of increased survival. The life-years gained were based on the 5-year long-term follow-up experience and an assumed annual 20% mortality risk for all patients thereafter. The health care costs were Euro 975 higher in the insulin group during the first year of follow-up, mainly due to a longer period of initial hospitalization related to the institution of multidose insulin. The estimated discounted gain in life-years of the insulin treatment was 0·94 years without and 0·66 with quality of life adjustment, respectively. The cost per life-year gained by intense insulin treatment was Euro 16900 and the cost per quality-adjusted life-year gained was Euro 24100. Thus the estimated cost-effectiveness ratios were relatively low.
Conclusion The results of the DIGAMI study indicate that intense insulin treatment after an acute myocardial infarction in patients with diabetes mellitus has an acceptable level of cost-effectiveness.
Key Words: Myocardial infarction, diabetes mellitus, survival, cost-effectiveness, insulin
f1 Correspondence: Björn Almbrand, MD, Department of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. R. Sadhu, A. C. Ang, L. A. Ingram-Drake, D. S. Martinez, W. A. Hsueh, and S. L. Ettner Economic Benefits of Intensive Insulin Therapy in Critically Ill Patients: The Targeted Insulin Therapy to Improve Hospital Outcomes (TRIUMPH) Project Diabetes Care, August 1, 2008; 31(8): 1556 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Kobelt, P Lindgren, A Singh, and L Klareskog Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial Ann Rheum Dis, August 1, 2005; 64(8): 1174 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N Buch, D. M Barton, G. I Varughese, E. Hodgson, and J. H. Scarpello A one-year retrospective audit of the DIGAMI protocol The British Journal of Diabetes & Vascular Disease, November 1, 2004; 4(6): 396 - 399. [Abstract] [PDF]
|
|
|
|
|
|
G Kobelt, K Eberhardt, and P Geborek TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden Ann Rheum Dis, January 1, 2004; 63(1): 4 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]
|
|
|
|
 |
|
 H. M. Krumholz, W. S. Weintraub, W. D. Bradford, P. A. Heidenreich, D. B. Mark, and A. D. Paltiel Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it? J. Am. Coll. Cardiol., August 21, 2002; 40(4): 603 - 615. [Full Text] [PDF]
|
|
|
|
|
|
S. H. Roman and M. R. Chassin Windows of Opportunity to Improve Diabetes Care When Patients With Diabetes Are Hospitalized for Other Conditions Diabetes Care, August 1, 2001; 24(8): 1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hildebrandt Intensive insulin treatment of diabetic patients with myocardial infarction is highly cost-effective Eur. Heart J., May 1, 2000; 21(9): 700 - 702. [PDF]
|
|